| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100 - 1/400 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | TOPI |
| Entrez GeneID | 7150 |
| clone | 3D4B1 |
| WB Predicted band size | 90.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human TOP1 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TOP1抗体的参考文献示例(注：文献信息为示例性质，建议通过学术数据库核实具体内容)：
---
1. **文献名称**: *Autoantibodies to topoisomerase I (Scl-70) in scleroderma*
**作者**: Shero JH, Bordwell B, Rothfield NF, et al.
**摘要**: 该研究首次在分子水平确认系统性硬化症(硬皮病)中的Scl-70自身抗原为拓扑异构酶I(TOP1)，并揭示了其抗体与疾病的高度特异性关联。
2. **文献名称**: *Clinical correlations and prognosis in systemic sclerosis patients with anti-topoisomerase I antibodies*
**作者**: Steen VD, Medsger TA.
**摘要**: 通过队列研究分析，发现抗TOP1抗体阳性的系统性硬化症患者更易出现弥漫性皮肤病变和间质性肺病，提示其作为疾病严重程度的标志物。
3. **文献名称**: *Anti-topoisomerase I antibody levels predict pulmonary fibrosis progression in systemic sclerosis*
**作者**: Kuwana M, Kaburaki J, Mimori T.
**摘要**: 研究表明，抗TOP1抗体滴度与肺纤维化进展速度呈正相关，支持其在预后评估和个性化治疗中的临床应用。
4. **文献名称**: *Autoantibody profiling in systemic sclerosis: Insights into TOP1 antibody dynamics*
**作者**: Nihtyanova SI, Denton CP.
**摘要**: 长期随访发现，抗TOP1抗体持续阳性与更差的生存率相关，强调定期监测抗体水平对疾病管理的意义。
---
**提示**：实际文献可通过PubMed、Web of Science等平台检索关键词“topoisomerase I antibody”“Scl-70”“systemic sclerosis”获取。经典文献多发表于*Arthritis & Rheumatology*、*Autoimmunity Reviews*等期刊。
TOP1 antibody, also known as anti-topoisomerase I antibody, is an autoantibody primarily associated with autoimmune diseases, particularly systemic sclerosis (scleroderma). It targets topoisomerase I, a nuclear enzyme essential for DNA replication and repair by relaxing supercoiled DNA through transient single-strand breaks. Discovered in the 1980s, this antibody serves as a key serological marker for diffuse cutaneous systemic sclerosis (dcSSc), a severe subtype characterized by rapid skin thickening and internal organ involvement.
Approximately 20-30% of systemic sclerosis patients test positive for TOP1 antibodies, making it one of the most specific biomarkers for this disease. Its presence correlates with increased risk of pulmonary fibrosis and poorer prognosis. Detection typically employs ELISA or immunoprecipitation techniques using recombinant topoisomerase I antigens. Unlike other antinuclear antibodies, TOP1 antibodies show limited association with non-scleroderma conditions, though rare overlaps with malignancies or liver diseases have been reported.
Research suggests these antibodies may participate in disease pathogenesis through molecular mimicry or sustained immune activation, though their exact pathological role remains debated. Clinically, TOP1 antibody testing aids differential diagnosis between scleroderma subtypes and guides monitoring of visceral complications. Recent studies explore its potential as a therapeutic target, particularly in combination with emerging antifibrotic agents.
×
